Active in New York
Chris Ryall is a Managing Director at Finsbury. Chris joined Finsbury’s London office in 2012, moving to the New York office in 2014. He specializes in advising clients on all aspects of financial communications, with a particular focus on complex transactions. Prior to joining Finsbury Chris worked for Anglo American, first in Corporate Finance and then managing strategic communications for the Group’s divestment program. His transaction experience includes Takeda’s acquisition of Shire, Express Scripts’ sale to Cigna, the merger of Praxair and Linde Group, Takeda’s acquisition of ARIAD Pharmaceuticals, McDermott International’s merger with CB&I, Post Holdings’ acquisitions of Weetabix and Bob Evans Farms, the sale of SABMiller to AB InBev, and the merger of Holcim and Lafarge. Chris holds a Bachelor of Business Science degree from the University of Cape Town, South Africa.